The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The role of BTK inhibitors in the treatment of MCL: ongoing trials and future outlooks
In this discussion, Tycel Phillips, MD, City of Hope, Duarte, CA, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, give an overview of the current role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). These agents have shown promise in the relapsed/refractory (R/R) setting, and several trials are continuing to explore the efficacy of BTKis in this disease. Dr Phillips and Dr Kamdar comment on the role of both covalent and non-covalent BTKis, and share their thoughts on the sequencing of these agents with other therapies. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
